Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation

The multikinase inhibitor sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of sorafenib using combination strategies is a major clinical c...

Descripción completa

Detalles Bibliográficos
Autores principales: Groenendijk, Floris H, Mellema, Wouter W, van der Burg, Eline, Schut, Eva, Hauptmann, Michael, Horlings, Hugo M, Willems, Stefan M, van den Heuvel, Michel M, Jonkers, Jos, Smit, Egbert F, Bernards, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Cancer Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312923/
https://www.ncbi.nlm.nih.gov/pubmed/25080865
http://dx.doi.org/10.1002/ijc.29113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312923/
https://www.ncbi.nlm.nih.gov/pubmed/25080865
http://dx.doi.org/10.1002/ijc.29113

Ejemplares similares